{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:13:54Z","timestamp":1790158434762,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T00:00:00Z","timestamp":1385596800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-244x-13-320","type":"journal-article","created":{"date-parts":[[2013,11,28]],"date-time":"2013-11-28T02:03:17Z","timestamp":1385604197000},"source":"Crossref","is-referenced-by-count":28,"title":["The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Lei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J","family":"Kinon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Succop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago R","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Ascher-Svanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,28]]},"reference":[{"key":"1494_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1192\/bjp.156.1.17","volume":"156","author":"MT Tsuang","year":"1990","unstructured":"Tsuang MT, Lyons MJ, Faraone SV: Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry. 1990, 156: 17-26. 10.1192\/bjp.156.1.17.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"1494_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/schbul\/sbm133","volume":"34","author":"J McGrath","year":"2008","unstructured":"McGrath J: Dissecting the heterogeneity of schizophrenia outcomes. Schizophr Bull. 2008, 34 (2): 247-248.","journal-title":"Schizophr Bull"},{"issue":"06","key":"1494_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1017\/S0033291710001893","volume":"41","author":"M Case","year":"2011","unstructured":"Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ: The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med. 2011, 41 (06): 1291-1300. 10.1017\/S0033291710001893.","journal-title":"Psychol Med"},{"issue":"1","key":"1494_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","volume":"68","author":"SZ Levine","year":"2010","unstructured":"Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68 (1): 86-92. 10.1016\/j.biopsych.2010.01.012.","journal-title":"Biol Psychiatry"},{"issue":"1\u20133","key":"1494_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.schres.2012.01.014","volume":"137","author":"SZ Levine","year":"2012","unstructured":"Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H: Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res. 2012, 137 (1\u20133): 141-146.","journal-title":"Schizophr Res"},{"issue":"4","key":"1494_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/JCP.0b013e3181e68e80","volume":"30","author":"SZ Levine","year":"2010","unstructured":"Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H: Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol. 2010, 30 (4): 446-449. 10.1097\/JCP.0b013e3181e68e80.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1494_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/schbul\/sbn120","volume":"36","author":"SZ Levine","year":"2010","unstructured":"Levine SZ, Rabinowitz J: Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010, 36 (3): 624-632. 10.1093\/schbul\/sbn120.","journal-title":"Schizophr Bull"},{"issue":"1\u20133","key":"1494_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.schres.2010.10.026","volume":"126","author":"SZ Levine","year":"2011","unstructured":"Levine SZ, Lurie I, Kohn R, Levav I: Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res. 2011, 126 (1\u20133): 184-191.","journal-title":"Schizophr Res"},{"key":"1494_CR9","volume-title":"Diagnostic and statistical manual of mental disorders 4th Ed. (DSM-IV-TR\u2122, 2000), 4 edn","author":"MB First","year":"2000","unstructured":"First MB: Diagnostic and statistical manual of mental disorders 4th Ed. (DSM-IV-TR\u2122, 2000), 4 edn. 2000, American Psychiatric Association: Washington, DC"},{"issue":"10","key":"1494_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991, 148 (10): 1301-1308.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1494_CR11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/ajp.155.6.751","volume":"155","author":"RW Buchanan","year":"1998","unstructured":"Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998, 155 (6): 751-760.","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1494_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/archpsyc.58.10.965","volume":"58","author":"JM Kane","year":"2001","unstructured":"Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, et al: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001, 58 (10): 965-972. 10.1001\/archpsyc.58.10.965.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"1494_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR: The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006, 32 (2): 214-219. 10.1093\/schbul\/sbj053.","journal-title":"Schizophr Bull"},{"issue":"9","key":"1494_CR14","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1016\/j.jcp.2011.01.048","volume":"230","author":"BG Levine","year":"2011","unstructured":"Levine BG, Stone JE, Kohlmeyer A: Fast analysis of molecular dynamics trajectories with graphics processing units-radial distribution function Histogramming. J Comput Phys. 2011, 230 (9): 3556-3569. 10.1016\/j.jcp.2011.01.048.","journal-title":"J Comput Phys"},{"issue":"1\u20133","key":"1494_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.schres.2012.01.004","volume":"135","author":"J Lyne","year":"2012","unstructured":"Lyne J, O\u2019Donoghue B, Owens E, Renwick L, Madigan K, Kinsella A, Clarke M, Turner N, O\u2019Callaghan E: Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophr Res. 2012, 135 (1\u20133): 128-133.","journal-title":"Schizophr Res"},{"issue":"1","key":"1494_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0920-9964(91)90053-T","volume":"5","author":"J Addington","year":"1991","unstructured":"Addington J, Addington D: Positive and negative symptoms of schizophrenia. Their course and relationship over time. Schizophr Res. 1991, 5 (1): 51-59. 10.1016\/0920-9964(91)90053-T.","journal-title":"Schizophr Res"},{"issue":"3","key":"1494_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/ajp.139.3.297","volume":"139","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC, Olsen SA, Dennert JW, Smith MR: Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry. 1982, 139 (3): 297-302.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1494_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archpsyc.1976.01770040068012","volume":"33","author":"WT Carpenter Jr","year":"1976","unstructured":"Carpenter WT, Bartko JJ, Carpenter CL, Strauss JS: Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry. 1976, 33 (4): 508-516. 10.1001\/archpsyc.1976.01770040068012.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"1494_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","volume":"39","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC: Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982, 39 (7): 784-788. 10.1001\/archpsyc.1982.04290070020005.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1494_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/schbul\/sbn041","volume":"34","author":"MJ Cuesta","year":"2008","unstructured":"Cuesta MJ, Peralta V: Current psychopathological issues in psychosis: towards a phenome-wide scanning approach. Schizophr Bull. 2008, 34 (4): 587-590.","journal-title":"Schizophr Bull"},{"issue":"3","key":"1494_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.neubiorev.2009.09.004","volume":"34","author":"VM Goghari","year":"2010","unstructured":"Goghari VM, Sponheim SR, MacDonald AW: The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev. 2010, 34 (3): 468-486. 10.1016\/j.neubiorev.2009.09.004.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"1494_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00005053-198905000-00006","volume":"177","author":"GP Guelfi","year":"1989","unstructured":"Guelfi GP, Faustman WO, Csernansky JG: Independence of positive and negative symptoms in a population of schizophrenic patients. J Nerv Ment Dis. 1989, 177 (5): 285-290. 10.1097\/00005053-198905000-00006.","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"1494_CR23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/schbul\/sbs100","volume":"38","author":"DC Javitt","year":"2012","unstructured":"Javitt DC: Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr Bull. 2012, 38 (5): 911-913. 10.1093\/schbul\/sbs100.","journal-title":"Schizophr Bull"},{"issue":"2","key":"1494_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1524-4733.2006.00083.x","volume":"9","author":"SL Tunis","year":"2006","unstructured":"Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006, 9 (2): 77-89. 10.1111\/j.1524-4733.2006.00083.x.","journal-title":"Value Health"},{"issue":"2","key":"1494_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276. 10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1494_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","volume":"23","author":"SR Kay","year":"1988","unstructured":"Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23 (1): 99-110. 10.1016\/0165-1781(88)90038-8.","journal-title":"Psychiatry Res"},{"key":"1494_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1471-244X-7-66","volume":"7","author":"DA Santor","year":"2007","unstructured":"Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL: Item response analysis of the positive and negative syndrome scale. BMC Psychiatry. 2007, 7: 66-10.1186\/1471-244X-7-66.","journal-title":"BMC Psychiatry"},{"issue":"2 Suppl 1","key":"1494_CR28","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD: Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008, 28 (2 Suppl 1): S20-S28.","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20133","key":"1494_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.schres.2008.06.018","volume":"105","author":"JM Kane","year":"2008","unstructured":"Kane JM, Assuncao-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT: The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res. 2008, 105 (1\u20133): 208-215.","journal-title":"Schizophr Res"},{"issue":"6","key":"1494_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A: Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009, 70 (6): 829-836. 10.4088\/JCP.08m04905.","journal-title":"J Clin Psychiatry"},{"key":"1494_CR31","volume-title":"Mplus - Statistical analysis with latent variables - user\u2019s guide","author":"B Muthen","year":"2007","unstructured":"Muthen B, Muthen L: Mplus - Statistical analysis with latent variables - user\u2019s guide. 2007, Muthen and Muthen: Los Angeles, 5","edition":"5"},{"key":"1494_CR32","first-page":"1","volume-title":"New developments and techniques in structural equation modeling","author":"B Muthen","year":"2001","unstructured":"Muthen B: Latent variable mixture modeling. New developments and techniques in structural equation modeling. Edited by: Marcoulides GA, Schumacker RE. 2001, Mahwah, NJ: Lawrence Erlbaum Associates, 1-33."},{"issue":"3","key":"1494_CR33","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1037\/1082-989X.8.3.338","volume":"8","author":"DJ Bauer","year":"2003","unstructured":"Bauer DJ, Curran PJ: Distributional assumptions of growth mixture models: implications for overextraction of latent trajectory classes. Psychol Methods. 2003, 8 (3): 338-363.","journal-title":"Psychol Methods"},{"issue":"3","key":"1494_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF02289473","volume":"31","author":"WH Pearson","year":"1966","unstructured":"Pearson WH: Estimation of a correlation coefficient from an uncertainty measure. Psychometrika. 1966, 31 (3): 421-433. 10.1007\/BF02289473.","journal-title":"Psychometrika"},{"issue":"12","key":"1494_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/archgenpsychiatry.2011.132","volume":"68","author":"R Gueorguieva","year":"2011","unstructured":"Gueorguieva R, Mallinckrodt C, Krystal JH: Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry. 2011, 68 (12): 1227-1237. 10.1001\/archgenpsychiatry.2011.132.","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"1494_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1017\/S0033291710002035","volume":"41","author":"TR Marques","year":"2011","unstructured":"Marques TR, Arenovich T, Agid O, Sajeev G, Muthen B, Chen L, Kinon BJ, Kapur S: The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med. 2011, 41 (7): 1481-1488. 10.1017\/S0033291710002035.","journal-title":"Psychol Med"},{"issue":"1\u20133","key":"1494_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.schres.2011.03.015","volume":"130","author":"V Stauffer","year":"2011","unstructured":"Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ: Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res. 2011, 130 (1\u20133): 11-19.","journal-title":"Schizophr Res"},{"issue":"3","key":"1494_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/schbul\/11.3.471","volume":"11","author":"TJ Crow","year":"1985","unstructured":"Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull. 1985, 11 (3): 471-486. 10.1093\/schbul\/11.3.471.","journal-title":"Schizophr Bull"},{"issue":"3","key":"1494_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway. Schizophr Bull. 2009, 35 (3): 549-562. 10.1093\/schbul\/sbp006.","journal-title":"Schizophr Bull"},{"issue":"5","key":"1494_CR40","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1176\/ajp.145.5.578","volume":"145","author":"WT Carpenter Jr","year":"1988","unstructured":"Carpenter WT, Heinrichs DW, Wagman AM: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988, 145 (5): 578-583.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1494_CR41","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1176\/ajp.154.4.466","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997, 154 (4): 466-474.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"1494_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.schres.2011.09.028","volume":"134","author":"VL Stauffer","year":"2012","unstructured":"Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR: Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res. 2012, 134 (2\u20133): 195-201.","journal-title":"Schizophr Res"},{"issue":"3","key":"1494_CR43","first-page":"365","volume":"29","author":"BJ Kinon","year":"1993","unstructured":"Kinon BJ, Kane JM, Chakos M, Munne R: Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull. 1993, 29 (3): 365-369.","journal-title":"Psychopharmacol Bull"},{"key":"1494_CR44","first-page":"547","volume":"5","author":"J Chen","year":"2011","unstructured":"Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP: Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Pref Adher. 2011, 5: 547-554.","journal-title":"Patient Pref Adher"},{"issue":"2","key":"1494_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.psychres.2008.10.009","volume":"169","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J: Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009, 169 (2): 97-100. 10.1016\/j.psychres.2008.10.009.","journal-title":"Psychiatry Res"},{"issue":"1\u20132","key":"1494_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/BF02245617","volume":"124","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996, 124 (1\u20132): 159-167.","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"1494_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","volume":"14","author":"CM Beasley Jr","year":"1996","unstructured":"Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996, 14 (2): 111-123. 10.1016\/0893-133X(95)00069-P.","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"1494_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al: Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007, 13 (9): 1102-1107. 10.1038\/nm1632.","journal-title":"Nat Med"},{"issue":"1","key":"1494_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eurpsy.2003.10.004","volume":"19","author":"C Arango","year":"2004","unstructured":"Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT: The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004, 19 (1): 21-26. 10.1016\/j.eurpsy.2003.10.004.","journal-title":"Eur Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-320\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:06:09Z","timestamp":1746057969000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1494"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-320","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,28]]},"article-number":"320"}}